Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.81 |
| ▸ | POLB | P06746 | 2/20 | 0.81 |
| ▸ | MAPT | P10636 | 5/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.75 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15271381 | 1.00 | SIRT6 (0.81) | SIRT6POLBMAPTALDH1A1ADRB1 | |
| SCHEMBL7048817 | 0.94 | MAPT (0.85) | SIRT6POLBMAPTALDH1A1ADRB1 | |
| SCHEMBL12952781 | 0.92 | SIRT6 (0.71) | SIRT6POLBMAPTALDH1A1ADRB1 | |
| SCHEMBL1851861 | 0.91 | MAPT (0.89) | SIRT6POLBMAPTALDH1A1ADRB1 | |
| SCHEMBL378458 | 0.91 | MAPT (0.96) | SIRT6POLBMAPTALDH1A1ADRB1 | |
| SCHEMBL29028271 | 0.90 | POLB (0.69) | SIRT6POLBMAPTALDH1A1ADRB1 | |
| SCHEMBL13159166 | 0.90 | SIRT6 (0.69) | SIRT6POLBMAPTALDH1A1ADRB1 | |
| SCHEMBL20639764 | 0.90 | SIRT6 (0.69) | SIRT6POLBMAPTALDH1A1ADRB1 | |
| SCHEMBL3891177 | 0.90 | MAPT (0.70) | SIRT6POLBMAPTALDH1A1ADRB1 | |
| SCHEMBL447471 | 0.90 | SIRT6 (1.00) | SIRT6POLBMAPTALDH1A1ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050120494-A1 | Triazacyclononane derivatives substituted on at least one of the nitrogen atoms with a substituted or unsubstituted 4'-aminophenyl group, for dyeing keratin fibres | L'OREAL S.A. (FR) | 2005-06-09 | — | — | US | disclosed |
| EP-1518860-A1 | Triazacyclononane derivatives substituted on at least one of the nitrogene atoms by a 4-aminophenyle group for dyeing keratinic fibres | L'OREAL (FR) | 2005-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050120494-A1 | Triazacyclononane derivatives substituted on at least one of the nitrogen atoms with a substituted or unsubstituted 4'-aminophenyl group, for dyeing keratin fibres | KRT18, TUBB6, TUBB1 | SIRT6 1570/4885POLB 415/4885MAPT 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.